t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
- PMID: 14513054
- DOI: 10.1038/sj.leu.2403091
t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
Abstract
Recent studies have shown that two recurrent translocations, t(4;14)(p16;q32) and t(11;14)(q13;q32), define distinct entities with different prognosis in multiple myeloma (MM). We addressed the issue of whether these illegitimate IGH rearrangements could contribute to the morphological heterogeneity of the malignant plasma cells (PC). Bone marrow aspirates of 178 untreated MM cases with successful molecular cytogenetics analysis using fluorescence in situ hybridization were reviewed. PC of 25/48 (52%) patients with t(11;14) exhibited a lymphoplasmacytoid morphology. Moreover, 25/27 (93%) of the cases with this morphological profile bore the t(11;14). In addition, both cytogenetics and morphological subtypes shared higher incidence of nonsecretory MM. In contrast, 17 out of 28 cases (61%) with t(4;14) exhibited PC with diffuse chromatin pattern. Interestingly, both t(4;14) translocation and immature morphology correlated with higher incidence of high tumor mass and chromosome 13 abnormality. In conclusion, our results suggest that a particular morphology can be the signature of chromosomal abnormalities in MM.
Comment in
-
Many and multiple myeloma(s).Leukemia. 2003 Oct;17(10):1943-4. doi: 10.1038/sj.leu.2403090. Leukemia. 2003. PMID: 14513042 Review. No abstract available.
Similar articles
-
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.Cancer Res. 1998 Dec 15;58(24):5640-5. Cancer Res. 1998. PMID: 9865713
-
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.Exp Oncol. 2007 Jun;29(2):116-20. Exp Oncol. 2007. PMID: 17704743
-
Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.Am J Surg Pathol. 2007 May;31(5):690-6. doi: 10.1097/01.pas.0000213399.87816.56. Am J Surg Pathol. 2007. PMID: 17460451
-
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Cancer Genet. 2011. PMID: 21356186 Review.
-
Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.Ann Oncol. 2000;11 Suppl 1:131-5. Ann Oncol. 2000. PMID: 10707795 Review.
Cited by
-
Multiple myeloma with t(11;14): unique biology and evolving landscape.Am J Cancer Res. 2022 Jul 15;12(7):2950-2965. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968339 Free PMC article. Review.
-
Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.Front Oncol. 2022 Aug 2;12:934008. doi: 10.3389/fonc.2022.934008. eCollection 2022. Front Oncol. 2022. PMID: 35982976 Free PMC article. Review.
-
Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.Cancer Sci. 2021 Sep;112(9):3645-3654. doi: 10.1111/cas.15073. Epub 2021 Jul 29. Cancer Sci. 2021. PMID: 34288263 Free PMC article.
-
Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.Cancer Med. 2024 Nov;13(21):e70382. doi: 10.1002/cam4.70382. Cancer Med. 2024. PMID: 39494582 Free PMC article.
-
Risk Stratification in Multiple Myeloma in Indian Settings.Indian J Hematol Blood Transfus. 2020 Jul;36(3):464-472. doi: 10.1007/s12288-019-01240-4. Epub 2019 Dec 14. Indian J Hematol Blood Transfus. 2020. PMID: 32647419 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical